Reclassification of obstetric antiphospholipid syndrome under the 2023 ACR/EULAR criteria: risk of under-recognition in patients with non-criteria antibodies and clinical implications
Tingwei Sheng, Yuqi Tang, Zhengwei Tan, Ling Liu, Qiaoding Dai · 2026
Read Reclassification of obstetric antiphospholipid syndrome under the 2023 ACR/EULAR criteria: risk of under-recognition in patients with non-criteria antibodies and clinical implications by Tingwei Sheng, Yuqi Tang, Zhengwei Tan, Ling Liu, Qiaoding Dai (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13631859.txt.
Description
Tingwei Sheng and co-authors rechecked pregnancy-related antiphospholipid syndrome cases under new 2023 criteria, in this 2026 study. The syndrome links certain antibodies to pregnancy loss. New scoring rules may miss patients whose only antibodies fall outside the standard panel.
Records covered 45 women, 41 with full lab history. Pregnancy loss was common, and about a third carried non-standard antibodies. Only a small share clearly met the new lab threshold, though more met it under generous assumptions. The authors warn the rules may under-recognize such patients. They urge care in applying the criteria at the clinic.
Catalog record
| CREATOR | Tingwei Sheng, Yuqi Tang, Zhengwei Tan, Ling Liu, Qiaoding Dai |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |